Objectives: To evaluate how combining fractional laser-based resurfacing treatments with targeted cosmeceuticals leads to sustained improvement in skin quality, with emphasis on collagen remodeling, texture refinement, and pigment balance.
Introduction: Skin quality has become a central focus of aesthetic dermatology, encompassing tone, texture, firmness, hydration, and clarity. While laser resurfacing offers significant short-term improvements, maintaining and enhancing those results requires long-term skin support. This talk explores how integrating resurfacing procedures with ongoing cosmeceutical use can achieve lasting improvements in skin quality, particularly for aging and pigment-prone skin.
Materials / method: A review of clinical data and expert consensus was conducted, examining studies involving fractional CO₂, Er:YAG, non-ablative lasers, and microneedling RF. This was combined with long-term studies of topical antioxidants, peptides, growth factors, and barrier-repair agents used post-procedure. Studies were selected with a preference for Asian or Fitzpatrick III–V populations.
Results: Fractional laser resurfacing improves texture and dermal collagen for up to 6–12 months.
Adjunctive use of L-ascorbic acid, peptides, and lipids post-resurfacing enhances epidermal integrity and extends visible results.
Longitudinal data support the role of antioxidant and peptide-rich skincare in maintaining radiance, reducing PIH recurrence, and supporting collagen remodeling.
Conclusion: Procedural interventions provide the catalyst for skin quality improvement, but sustained results rely on ongoing skincare. A long-term, phased skincare protocol using clinically validated actives enhances outcomes and prevents regression, especially in pigment-prone skin types. Dermatologists should view resurfacing and cosmeceuticals as partners in long-term aesthetic care.
Disclosures
Did you receive any funding to support your research for this TOPIC?
No
Were you provided with any honoraria, payment or other compensation for your work on this study?
No
Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No
Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No
This work was not supported by any direct or non direct funding. It is under the author's own responsability
